Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.

Caroline SchmidbauerRaphael SchubertAngelika SchützCornelia SchwankeJulian LuhnEnisa GuticRoxana PirkerTobias LangThomas ReibergerHans HaltmayerMichael Gschwantler

Published in: PloS one (2020)

G/P given as DOT along with OST in PWIDs with high risk of non-adherence to DAA therapy resulted in similarly high SVR rates (94.6%) as in patients with presumed "excellent compliance" under standard drug intake.

Keyphrases

hepatitis c virus
pain management
electronic health record
stem cells
emergency department
big data
metabolic syndrome
weight gain
bone marrow
machine learning
adipose tissue
hiv infected
adverse drug
glycemic control
weight loss
energy transfer
cell therapy